GEMINA LABS ANNOUNCES PRIVATE PLACEMENT

October 20, 2021

GEMINA LABORATORIES LTD. 

News Release 

October 20, 2021 

GEMINA LABS ANNOUNCES PRIVATE PLACEMENT 

October 20, 2021, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to announce a non-brokered private placement offering (the  “Offering”) of up to 3,636,363 units at a price of $0.55 per unit (each, a “Unit”). Each Unit consists of one  common share (a “Common Share”) of Gemina and one-half of one Common Share purchase warrant  (each whole warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common  Share at an exercise price of $0.80 per Common Share for a period of 24 months from the closing date of  the Offering. The Offering is expected to raise gross proceeds of C$2,000,000. The Company may pay  finder’s fees in connection with this placement of up to 8.0% of the gross proceeds. 

The net proceeds of the Offering, along with existing funds, will be deployed towards the ongoing  development, manufacturing and final regulatory review of the Company’s initial rapid diagnostic test  using our breakthrough proprietary chemistry. Additionally, it will be applied to ongoing research and  development work related to new diagnostics tests already in process, as well as general working capital.  The securities issued under the Offering will be subject to a statutory hold period in Canada expiring four  months and one day from the Closing Date. 

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities  in the United States. The securities have not been and will not be registered under the United States  Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be  offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act  and applicable state securities laws or an exemption from such registration is available. 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  biochemistry that powers next-generation testing platforms for a wide range of pathogens that affect  human health and wellness. Our technology drives testing platforms that are fast, affordable and  accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing  of COVID-19, influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include, without limitation, statements regarding the anticipated proceeds to be raised  under the Offering; the use of any proceeds raised under the Offering; and any finder’s fees to paid in  connection with the Offering. Information and statements which are not purely historical fact are forward looking statements. Forward-looking information and statements involve and are subject to assumptions  and known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. These risks and uncertainties include delays in obtaining required regulatory approvals for the  Offering; market uncertainty; and the inability of the Company to raise the anticipated proceeds under  the Offering. Although the Company believes that any forward-looking information and statements herein  are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in  such information and statements, there can be no assurance that any such forward-looking information  and statements will prove to be accurate, and accordingly readers are advised to rely on their own  evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546  

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.